Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials

IMPORTANCE: Flortaucipir positron emission tomography (PET) scans, rated with a novel, US Food and Drug Administration–approved, clinically applicable visual interpretation method, provide valuable information regarding near-term clinical progression of patients with Alzheimer disease (AD) or mild c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ming, Pontecorvo, Michael J., Devous, Michael D., Arora, Anupa K., Galante, Nicholas, McGeehan, Anne, Devadanam, Catherine, Salloway, Stephen P., Doraiswamy, P. Murali, Curtis, Craig, Truocchio, Stephen P., Flitter, Matthew, Locascio, Tricia, Devine, Marybeth, Zimmer, Jennifer A., Fleisher, Adam S., Mintun, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885097/
https://www.ncbi.nlm.nih.gov/pubmed/33587110
http://dx.doi.org/10.1001/jamaneurol.2020.5505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885097/
https://www.ncbi.nlm.nih.gov/pubmed/33587110
http://dx.doi.org/10.1001/jamaneurol.2020.5505

Ejemplares similares